Genetic Statistics

Share Statistics

Genetic has 145.42M shares outstanding. The number of shares has increased by -8.06% in one year.

Shares Outstanding	145.42M
Shares Change (YoY)	-8.06%
Shares Change (QoQ)	0%
Owned by Institutions (%)	0%
Shares Floating	27.94M
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 25.84K, so 0.53% of the outstanding shares have been sold short.

Short Interest	25.84K
Short % of Shares Out	0.53%
Short % of Float	0.56%
Short Ratio (days to cover)	999.99

Valuation Ratios

The PE ratio is -0.78 and the forward PE ratio is null. Genetic's PEG ratio is 0.01.

PE Ratio	-0.78
Forward PE	n/a
PS Ratio	1.22
Forward PS	n/a
PB Ratio	5.1
P/FCF Ratio	-0.96
PEG Ratio	0.01

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Genetic.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.48.

Current Ratio	0.88
Quick Ratio	0.83
Debt / Equity	0.48
Debt / EBITDA	-0.08
Debt / FCF	-0.09
Interest Coverage	-126.64

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$139.36K
Profits Per Employee	$-218.49K
Employee Count	55
Asset Turnover	1.24
Inventory Turnover	18.21

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.48, so Genetic's price volatility has been higher than the market average.

Beta	0.48
52-Week Price Change	n/a
50-Day Moving Average	0.76
200-Day Moving Average	1.48
Relative Strength Index (RSI)	47.23
Average Volume (20 Days)	n/a

Income Statement

In the last 12 months, Genetic had revenue of 7.66M and earned -12.02M in profits. Earnings per share was -2.73.

Revenue	7.66M
Gross Profit	3.9M
Operating Income	-6.54M
Net Income	-12.02M
EBITDA	-11.43M
EBIT	-11.97M
Earnings Per Share (EPS)	-2.73

Full Income Statement

Balance Sheet

The company has 1.02M in cash and 875.19K in debt, giving a net cash position of 145.42K.

Cash & Cash Equivalents	1.02M
Total Debt	875.19K
Net Cash	145.42K
Retained Earnings	-166.38M
Total Assets	6.19M
Working Capital	-500.09K

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -9.68M and capital expenditures -32.97K, giving a free cash flow of -9.71M.

Operating Cash Flow	-9.68M
Capital Expenditures	-32.97K
Free Cash Flow	-9.71M
FCF Per Share	-2.2

Full Cash Flow Statement

Margins

Gross margin is 50.94%, with operating and profit margins of -85.29% and -156.78%.

Gross Margin	50.94%
Operating Margin	-85.29%
Pretax Margin	-156.78%
Profit Margin	-156.78%
EBITDA Margin	-149.13%
EBIT Margin	-85.29%
FCF Margin	-126.71%

Dividends & Yields

GENE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for GENE.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on Dec 14, 2023. It was a backward split with a ratio of 1:5.

Last Split Date	Dec 14, 2023
Split Type	backward
Split Ratio	1:5

Scores

Altman Z-Score	-32.15
Piotroski F-Score	2

Genetic Technologies Limi... (GENE)